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Reduced Responsiveness to Epoetin at Re-exposure after Prolonged 
Epoetin-free Period in Anemic Hemodialysis Patients with End-stage 
Renal Disease
Aim To determine if temporary discontinuation of epoetin therapy in anemic 
patients with end stage renal disease (ESRD) influences their responsiveness 
to epoetin.
Methods We performed a post hoc analysis of the data from two consecutive 
single-center randomized trials (T1 and T2) comparing the efficacy of two 
epoetin products (E1 and E2) in anemic patients with ESRD. The analysis 
included a subset of 44 patients who participated in both trials and were not 
receiving epoetin in the period (median, 12 months; range 5-15) between the 
trials due to epoetin shortage. Two co-primary outcomes were average weekly 
hemoglobin difference from the baseline and average weekly epoetin dose.
Results With adjustment for potential differences between E1 and E2, aver-
age weekly hemoglobin difference of 1.21 g/dL from the baseline was lower 
in T2 than that of 1.71 g/dL in T1: difference -0.49 (95% confidence inter-
val [CI], –0.68 to –0.29; P<0.001). Average weekly epoetin dose of 107 IU/
kg in T2 was higher than 96 IU/kg in T1 (ratio, 1.13; 95% CI, 1.04-1.24; 
P = 0.009). With additional adjustment for within-subject changes in base-
line covariates from T1 to T2 (baseline hemoglobin, body mass index, serum 
albumin, ferritin and transferrin saturation, intact parathormone, C-reactive 
protein, dialysis dose, and use of angiotensin converting enzyme inhibitors), 
hemoglobin response remained lower (adjusted difference, -0.44 g/dL; 95% 
CI, -0.73 to -0.16; P = 0.004) and weekly epoetin dose remained higher in T2 
than inT1 (adjusted ratio, 1.17; 95% CI, 1.03-1.34; P = 0.016).
Conclusions In patients with ESRD, responsiveness to epoetin was lower in 
T2 after a period of epoetin therapy discontinuation than in T1 epoetin trial. 
Since this could not be explained by within-subject changes in factors known 
to affect response to epoetin, a prolonged withdrawal of epoetin in patients 
with ESRD might independently contribute to a reduced responsiveness to 
epoetin at a later re-exposure.
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Treatment of anemia with recombinant human 
erythropoietin (epoetin) is a standard care for 
patients suffering from chronic renal failure. In 
these patients, correction of anemia confers the 
benefits of reduced cardiovascular morbidity and 
mortality and improved quality of life (1). Typi-
cally, the response to epoetin varies considerably, 
both between and within subjects. This is mani-
fested as a variability in time needed to attain 
anemia correction in previously anemic patients 
and as a variability in the epoetin dose require-
ments for attainment and maintenance of cer-
tain hemoglobin levels (2). There are several well-
defined factors known to reduce responsiveness 
to epoetin: iron deficiency, especially absolute 
iron deficiency usually defined as transferrin sat-
uration <20% combined with serum ferritin lev-
els <100 ng/mL; on-going infection or inflam-
mation, diagnosed in patients with C-reactive 
protein levels of >30 mg/mL (especially patients 
with >50 mg/mL need higher epoetin doses); 
neglected secondary hyperparathyroidism (al-
though there is no consensus about the “critical” 
levels of the intact parathormone); inadequately 
low dialysis dose, as patients with Kt/V ≤1.2 or 
urea reduction ratio ≤65% can be expected to re-
spond poorly; and overall poor nourishment or 
nutrition, as patients with serum albumin <30 g/
L may be expected to respond poorly (2-8). Fur-
thermore, higher epoetin dose requirements are 
associated with the intravenous, as opposed to 
subcutaneous, route of epoetin delivery, female 
sex, use of high-dose of inhibitors of angiotensin-
converting enzyme (ACE), aluminum overload, 
carnitine deficiency, and a higher level of oxida-
tive stress. In situations where patients suffer 
from other causes of anemia beside renal failure, 
eg, hemolysis, hemoglobinopathies, cancer, ane-
mia-inducible therapies, and nutrient deficien-
cies (folate, vitamin B12, and vitamin C), respon-
siveness to epoetin is also reduced (2-8).
The question of improvement of response 
to epoetin in patients with chronic renal fail-
ure has attracted much attention, mainly with 
the goal of improving the benefits for the pa-
tient and the cost-effectiveness of epoetin thera-
py. Although epoetin has been in clinical use for 
this indication for almost two decades, the con-
tinuous treatment with epoetin is still rather ex-
pensive (5-9). It is for the economical reasons 
that shortages of epoetin are not uncommon in 
financially less privileged countries like Croatia, 
and many patients with renal disease in need of 
epoetin receive it only intermittently. Such an in-
adequate renal anemia management negatively 
affects morbidity, mortality, and quality of life in 
these patients. Considering the contribution of 
a prolonged anemia to the overall “uremic toxic-
ity” (10), and considering that both anemia and 
“uremic toxicity” may affect the response to epo-
etin (8), we assumed that the practice of epoetin 
withdrawal might have an additional drawback 
in that it might result in a reduced responsive-
ness to epoetin once the treatment has been re-
established. Since a trial designed specifically to 
investigate the effects of “off-epoetin” periods 
on epoetin responsiveness would not be ethically 
justified, we performed a post hoc analysis of data 
on a group of patients with end-stage renal dis-
ease (ESRD) on hemodialysis maintenance ther-
apy who participated in two consecutive clinical 
trials of epoetin efficacy and who were deprived 
of epoetin during the time between the trials due 
to financial reasons.
Patients and methods
The analysis included patients with ESRD who 
participated in both consecutive single-center 
prospective randomized 12-week clinical trials 
(T1 and T2) that compared efficacy of two re-
combinant human erythropoietin preparations 
(E1 and E2) (11). The T1 and T2 trials com-
pared the efficacy of two epoetin products, E1 
and E2, based on a between-subject comparison 
with adjustment for the effects of known con-
founders of responsiveness to epoetin (“baseline 
covariates”) (11). The average time of 12 months 
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(range, 5-15) between the trials was an “off-epo-
etin” period during which the patients again be-
came severely anemic.
Both trials were approved by the local Eth-
ics Committee of Holy Ghost General Hospital, 
Zagreb, and the patients were enrolled after they 
had given a written informed consent. The iden-
tical protocol was used in both trials (11). The di-
alysis conditions and equipment (membranes, 
dialyzers, and tubing) were not changed and 
the dialysis water quality was kept in line with 
the standards and recommendations (12,13) 
throughout both trials and the period in-be-
tween.
Trial protocols
For both trials, the patients were eligible if main-
tained on regular hemodialysis (3 times a week, 
approximately 4 hours per session), were ≥18 
years of age, and were severely anemic (hemoglo-
bin <9.5 g/dL). Patients were excluded if they 
had poorly controlled hypertension (systolic 
blood pressure >180 mm Hg or diastolic blood 
pressure >100 mm Hg), absolute iron deficiency 
defined as transferrin saturation (TSAT) <20% 
and serum ferritin <100 ng/mL, vitamin B12 or 
folic acid deficiency, hyperparathyroidism with 
suspect osteitis fibrosa, other causes of anemia 
(eg, continuous blood loss, hemolysis, or hemo-
globinopathies), pregnancy or lactation, on-going 
chronic or acute inflammatory disease or infec-
tion within 30 days before enrollment, malig-
nant disease, and serum albumin levels <30 g/L. 
Patients were not to receive blood transfusions, 
recombinant erythropoietin, cytotoxic agents, ra-
diation therapy or immune-suppressants within 
30 days before the enrollment.
Epoetin preparations compared in the two 
trials were epoetin omega (Epomax, Lek d.d., Slo-
venija and Elanex Pharma, WA, USA) and epoe-
tin alfa (Eprex®, Janssen-Cilag, Switzerland). The 
preparation were supplied as 1 mL prefilled sy-
ringes containing 2000, 4000, or 8000 IU of ep-
oetin. Epoetin was administered subcutaneously 
in the upper arm, twice weekly, after the first and 
the last dialysis session, according to the post-di-
alysis (“dry”) body weight determined in patients 
wearing indoor clothing without shoes. The dose 
to be administered (IU) was calculated from 
the scheduled dose (IU/kg) and rounded to the 
nearest hundred. The starting dose of 2 × 50 IU/
kg was not changed for the initial 4 weeks. There-
after, it was gradually adjusted to achieve 0.25-
0.30 g/dL of weekly hemoglobin (Hb) increase 
rate and to reach and maintain the target Hb lev-
el of 10-12 g/dL and at least 1.5 g/dL above the 
baseline value. Baseline was determined as an av-
erage of 2 values determined over a 2-week pre-
trial screening period. Folic acid and vitamin B12 
were supplemented routinely to all patients (1.0-
5.0 mg/d orally and 200-500 IU once a month 
intravenously, respectively). Iron saccharate was 
supplied intravenously to keep TSAT >20% and 
serum ferritin >100 ng/mL (1 × 50 mg/week to 
3 × 100 mg/week, depending on the iron status). 
A continuous follow-up was ascertained through 
regular weekly visits.
Two co-primary efficacy endpoints were de-
termined. One endpoint was average weekly dif-
ference in hemoglobin from the baseline value 
determined as time-adjusted area under the curve 
(AUC) of weekly differences (14). Baseline he-
moglobin value was subtracted from each weekly 
hemoglobin value of the treatment period; AUC 
of differences was calculated and “adjusted” for 
the number of weeks spent in the trial to yield a 
weekly average (g/dL). The other endpoint was 
average weekly epoetin dose determined for each 
patient as the sum of weekly doses (IU/kg) per 
number of weeks in the trial (14).
Patients
A total of 56 patients who completed 12 weeks 
of treatment (regular epoetin and nutrients de-
livery and regular dialysis and follow-up) in T1 
were included in T2. In T2, one of these patients 
died of cerebrovascular insult early in week 1. Of 
the remaining 55 patients, 11 experienced con-
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founding events either in T1 or in T2: 5 patients 
received transfusions (a unit of packed red cells) 
either before the first epoetin dose in the trial or 
during week 1 due to low entry hemoglobin lev-
el; 6 patients received transfusions in weeks 2-
5 due to blood loss caused by rectal bleeding (1 
patient), metrorrhagia (1 patient), dialyzer clots 
with hemolysis (1 patient), upper gastrointesti-
nal bleeding (2 patients) or accidental blood loss 
(1 patient). This left 44 patients who completed 
both trials with regular treatment and follow-up 
and did not experience co-morbidity, including 
infection or inflammation, or other treatments 
(eg, cytotoxic or immunosuppressive therapy) 
that could have interfered with responsiveness 
to epoetin. These patients were included in the 
analysis.
Statistical analysis
Average weekly Hb difference from the baseline 
and average weekly epoetin dose were taken as 
co-primary outcomes. In addition, summary sta-
tistics was reported for all variables determined 
in T1 and T2 in all 44 patients.
Analysis of the co-primary outcomes was 
performed in two steps. The first step was to es-
timate the unadjusted difference between T2 
and T1. Since each patient received two differ-
ent epoetin products, one in T1 (E1 or E2) and 
the other one in T2 (E2 or E1), repeated mea-
sures analysis of variance (ANOVA) was ap-
plied, with two within-subject factors, each with 
two levels: trial (T1 or T2) and epoetin prod-
uct (E1 or E2). The second step was to estimate 
the adjusted difference between T2 and T1, ie, 
the within-subject differences in response to ep-
oetin (T2-T1) while further accounting for po-
tential effects of within-subject changes in the 
known confounding factors of response to epoe-
tin (“baseline covariates”). The confounding fac-
tors included hemoglobin (severity of anemia); 
serum ferritin and TSAT (available iron); se-
rum CRP (inflammation); dialysis dose as urea 
reduction ratio (URR); serum albumin (over-
all nutritional status and inflammation); body 
mass index (might affect availability of subcuta-
neous epoetin); serum levels of intact parathor-
mone (iPTH) (level of hyperparathyroidism); 
and proportion of patients using ACE inhibitors 
(2-8). For this purpose, each of the co-primary 
outcomes was analyzed by multiple regression on 
repeated measures data (15). In this procedure, 
data on the outcome and independent variables 
were entered as two values per patient, one from 
T1 and the other from T2. The procedure parti-
tioned the variability of the outcome variable to 
differences between and within patients. The dif-
ference within patients was further partitioned 
among the within-subject covariates (analysis of 
covariance). Regression of the outcome variable 
on the “trial” factor disclosed whether higher or 
lower values were associated with either of the 
trials (times of measurement) (16). Value of the 
regression coefficient was the mean difference be-
tween the two trials.
Data on average weekly epoetin dose were 
ln-transformed for both analyses to meet the 
normality assumption. We used NCSS 2005 
(NCSS, Kaysville, UT, USA) statistical software 
for all data analyses. P<0.05 was considered sta-
tistically significant.
Results
Baseline patient characteristics
Anemia in our patients was less pronounced at 
the start of T2 (Table 1). The values of serum 
ferritin, TSAT, albumin, CRP, iPTH, and URR 
were satisfactory at baseline of both trials (Ta-
ble 1). The same 3 patients had CRP >30 mg/L 
at the start of T1 and T2. For one additional pa-
tient who had serum CRP >30 mg/L at the start 
of T2, the actual value was 33 mg/L, as com-
pared to 29 mg/L at the start of T1. The same 8 
patients had TSAT <20% at the beginning of T1 
and T2. None of the patients was treated with l-
carnitine or vitamin C during T1 and T2 or in-
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between period, while the same 22 patients were 
treated with calcitriol (with calcitriol-free peri-
ods).
Iron availability
In both trials, serum ferritin and TSAT dropped 
after the initial 4 weeks of treatment and then 
again increased toward the end of the trials (iron 
supplementation). They were continuously kept 
at satisfactory levels (Table 2).
Responsiveness to epoetins
In both trials, patients experienced a consider-
able Hb increase with typical inter-individual 
variability (Figure 1). However, the increase in 
Hb seemed more pronounced and the delivered 
epoetin doses were somewhat lower in T1 than 
in T2 (Figure 1). Accounting for potential differ-
ences between the two epoetin products, Hb re-
sponse defined as average weekly Hb difference 
from the baseline was significantly lower in T2 
than in T1(mean difference T2-T1= -0.49 g/
dL, P<0.001), whereas the mean weekly epoet-
in dose was around 13% higher in T2 than in T1 
(P = 0.009) (Table 3).
In the second-step analysis, the differenc-
es between T2 and T1 were estimated, account-
ing not only for the differences between epoetin 
products, but with further adjustment for with-
in-subject differences in the use of ACEi, base-
line Hb, CRP, iPTH, URR, serum albumin lev-
els, serum ferritin and TSAT, and BMI (Table 
4). Hb response remained significantly lower in 
T2 in comparison with T1 (Table 4). The re-
gression coefficient (B) for factor “trial” indicat-
ed a mean difference T2-T1 of -0.44 g/dL (95% 
CI, -0.73 to -0.16). Also, the average weekly epo-
etin dose remained significantly higher in T2 in 
comparison with T1 (Table 4). The coefficient 
(B=0.162) for factor “trial” obtained by regres-
sion of the ln-transformed data indicated a geo-
metric means ratio T2/T1 of 1.17 (95% CI, 
1.03-1.34), ie, around 17% higher average weekly 
epoetin dose in T2 in comparison with T1.
Table 1. Characteristics and baseline values of measured para-
meters in 44 patients included in two epoetin trials*
Baseline values Reference
Parameter trial 1 trial 2 values†
Age (y)   54 ± 12   56 ± 12   NA
HD vintage (mo)  36 (12–88)  48 (25–101)   NA
BMI (kg/m2) 25.7 ± 3.9 24.8 ± 4.1 18.5-25
Albumin (g/L) 39.3 ± 4.8 38.1 ± 5.2   35-52
URR (%)  71 (66-74)  70 (66-73)   NA
Hb (g/dL)  7.6 ± 0.6  7.8 ± 0.8 11.9-15.7
MCV (fL) 92.5 ± 3.4 93.0 ± 4.2 83.0-97.2
CRP (mg/L)  14.0 (10.3-22.0)  15.5 (11.3-23.0)    0-10.0
CRP>30 mg/L 
 (No. of patients)
  3   4   NA
TSAT (%)  29.2 (21.9-40.8)  29.5 (21.9-46.1) 22.6-41.6
TSAT<20% 
 (No. of patients)
  8   8   NA
Ferritin (ng/mL) 285 (131-768) 577 (300-1003)   10-120
iPTH (pmol/L)  16.6 (7.4-43.2)  18.5 (6.3-38.3)  0.1-6.0
Systolic BP (mm Hg)  148 ± 21  154 ± 22  100-120
Diastolic BP (mm Hg)   84 ± 8   87 ± 9   60-80
Use of ACEi 
 (No. of patients)
  7   8   NA
*Abbreviations: HD – hemodialysis; BMI – body mass index; URR – urea reduction 
ratio; Hb – hemoglobin; MCV – mean corpuscular volume; CRP – C-reactive protein; 
TSAT – transferrin saturation; iPTH – intact parathormone; BP – blood pressure; ACEi 
– angiotensin converting enzyme inhibitors; NA – not applicable. Data are presented 
as either mean ± standard deviation or median with interquartile range.
†Holy Ghost General Hospital Laboratory.
Table 2. Development of serum ferritin and transferrin saturati-
on (TSAT) over time in 44 patients included in two epoetin trials
Value (median, interquartile range)
Time variable trial 1 trial 2
Baseline:
 ferritin (ng/mL) 285 (131-768) 577 (300-1033)
 TSAT (%)  29.2 (21.9-40.8)  29.5 (21.9-46.1)
After 4 weeks:
 ferritin (ng/mL) 241 (100-541) 317 (197-873)
 TSAT (%)  22.0 (17.7-27.7)  20.8 (17.3-26.1)
After 8 weeks:
 ferritin (ng/mL) 352 (210-727) 417 (240-890)
 TSAT (%)  21.9 (19.1-31.5)  22.3 (19.5-27.6)
After 12 weeks:
 ferritin (ng/mL) 343 (188-659) 350 (192-702)
 TSAT (%)  25.1 (21.4-31.5)  23.2 (17.9-28.2)
Table 3. Differences between trial 2 (T2) and trial 1 (T1) in 
average weekly hemoglobin difference vs baseline and ave-
rage weekly epoetin dose, with adjustment for the differences 
between two epoetin products*
Average weekly hemoglobin 
difference vs baseline (g/dL)
Ln (average weekly 
epoetin dose) (IU/kg) *
Predictors F P F P
Subject  2.82 <0.001  1.43  0.122
Treatment 58.29 <0.001 19.28 <0.001
Trial 23.31 <0.001  7.52  0.009
T2-T1 difference   -0.49  1.13
 (95% CI) (-0.68 to -0.29) (1.04-1.24)
*Difference between means for the ln-transformed data (average weekly epoetin 
dose) is expressed as an exponent, ie, geometric means ratio.
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Discussion
Treatment of renal anemia with epoetin is long-
lasting and rather expensive. Much effort has 
been put into optimization of the use of epoet-
in with the intention of improving both bene-
fits for the patients and cost-effectiveness of the 
treatment (5-9), which is of special interest in fi-
nancially less privileged countries where shortag-
es of epoetin due to financial reasons are not un-
common. To assess if the withdrawal of epoetin 
treatment, which leads to a relapse of anemia in 
patients with ESRD, would affect responsive-
ness to epoetin at a later re-exposure indepen-
dently of other contributing factors, we used 
the data on patients with ESRD who participat-
ed in two consecutive epoetin clinical trials (T1 
and T2) (11) and were not treated with epoetin 
during the in-between period due to a shortage 
of epoetin. Therefore, we had a situation of epo-
etin withdrawal (time between the trials) after a 
period of treatment (T1), followed by a re-expo-
sure (T2). The fact that the two trials were con-
ducted according to identical protocols allowed 
for (a) regular follow-up on different parameters, 
including the known confounders of response to 
epoetin; (b) uniform dose-adjustment algorithm 
with identical targeted hemoglobin development 
and iron and nutrients supplementation strat-
egies; and (c) exclusion of confounding events 
Table 4. Summary of the within-subject analysis of covariance and regression coefficients (B) for the two co-primary outcomes in trial 
1 (T1) and trial 2 (T2)*
Average weekly hemoglobin difference vs baseline Average weekly epoetin dose†
Independent variables F-ratio B P F-ratio B P
ACEi  0.177 -0.098  0.677  0.066   0.027 0.799
Albumin  4.409   0.047  0.044  3.621 -0.019 0.065
Baseline hemoglobin  2.375 -0.260  0.133  0.246 -0.038 0.623
BMI  1.210 -0.094  0.279  1.627   0.049 0.211
CRP  2.371   0.005  0.133  0.246 -0.0007 0.623
Ferritin  0.338   0.0001  0.565  2.646 -0.0001 0.113
TSAT  0.420 -0.004  0.521  0.879   0.002 0.355
iPTH  5.727   0.02  0.023  6.024 -0.009 0.020
URR  2.805 -0.056  0.103  1.196   0.017 0.282
Treatment (E1) 37.160 -0.692 <0.001 10.044   0.162 0.003
Trial (T2)  9.602 -0.442  0.004  6.404   0.162 0.016
Difference between subjects  2.699  0.002  1.333 0.197
*Abbreviations: ACEi – angiotensin converting enzyme inhibitors, BMI – body mass index, CRP – C-reactive protein, TSAT – transferrin saturation, iPTH – intact parathormone, URR 
– urea reduction ratio.
†Natural logarithm.
Figure 1. Development of hemoglobin (Hb) and weekly epoetin doses over time in 44 
patients in trial 1 (T1) and trial 2 (T2).
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both before and during the epoetin treatment 
periods, including concomitant treatments that 
might have been anemia-inducible (like cytotox-
ic or immunosuppressive agents) or “anemia-im-
proving”, like l-carnitine (17). Furthermore, both 
trials were conducted in the same center with-
in a relatively short time-period. Approximately 
2 years and 8 months had elapsed between the 
“first patient in” (T1) and “last patient out” (T2). 
During that time period, the dialysis water qual-
ity was maintained in line with the standards and 
recommendations minimizing the risk of possi-
ble interference of chemical or biological impu-
rities, and the dialysis conditions and equipment 
did not change. Although the two trials were rel-
atively short in duration, 12 weeks has been rec-
ognized as a period sufficient for estimation of a 
response to epoetin (18), and the outcomes used 
for this analysis have been confirmed as valid and 
informative for the purpose (14).
We found a reduced responsiveness to epo-
etin (higher doses of epoetin and lower Hb re-
sponse) at re-exposure (T2) in comparison with 
the period before the withdrawal (T1) in our 
group of patients. This phenomenon could not 
be fully accounted for by the apparent difference 
between the two epoetin products that were used 
or by within-subject variations in known con-
founders of response to epoetin. In particular, 
the iron parameters indicated a satisfactory and 
comparable iron availability, mobilization, and 
utilization throughout the treatment periods. 
Cumulatively, these observations suggest that the 
“off-epoetin” period itself was a contributing fac-
tor. Our analysis did not distinguish between the 
effect of “epoetin withdrawal” and a 12 months 
longer “history of hemodialysis” (HD vintage) in 
our patients at the start of the re-exposure treat-
ment period. However, there has been no evi-
dence that increased HD vintage, as an isolated 
factor, might be a source of within-subject vari-
ability in response to epoetin, ie, that responsive-
ness to epoetin would decrease over time in pa-
tients on chronic epoetin treatment who receive 
an adequate overall care for renal failure simply 
because of the elapse of time (3,4,19). Therefore, 
our results indirectly suggest that discontinua-
tion of epoetin treatment independently con-
tributed to reduced responsiveness to epoetin 
at re-exposure. The current analysis provides no 
clues about the potential mechanisms involved. 
However, it seems plausible to assume that a 
combination of several factors that might have 
worsened during the “off-epoetin” period, none 
of which should have necessarily caused changes 
in commonly monitored parameters, could have 
affected responsiveness to epoetin in this group 
of patients. It is well known that anemia contrib-
utes to the overall “uremic toxicity” (10). Fur-
thermore, both anemia and “uremic toxins” are 
known to contribute to oxidative stress through 
tissue hypoxia, alterations in catecholamine me-
tabolism, or suppression of the endogenous 
“scavenging” potential (8), and that oxidative 
stress reduces responsiveness to epoetin by pro-
moting lipid peroxidation in the cell membranes, 
leading to increased red cell fragility and reduced 
life-span, and through propagation of inflamma-
tion (8).
T1 and T2 analysis revealed a difference in re-
sponsiveness to epoetin as well as a difference in 
response to two epoetin products. It also suggest-
ed that better responsiveness to epoetin, ie, low-
er doses and greater Hb response, was associated 
with higher serum albumin concentration and 
higher serum iPTH values. The fact that other 
factors, such as iron availability, inflammation, or 
dialysis dose were not identified as “statistically 
significant” does not imply their irrelevance for 
responsiveness to epoetin. Rather it implies that 
within-subject variations in these parameters be-
tween the two treatment periods were modest 
and did not affect the analyzed outcomes to a rel-
evant extent. Although all the patients had serum 
albumin levels >30 g/L at the beginning of either 
trial, better responsiveness to epoetin was associ-
ated with higher serum albumin. Low serum al-
bumin, ie, the acute-phase response delineated 
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by low albumin and transferrin and high CRP 
and ferritin levels, was suggested as the most im-
portant predictor of poorer response to epoetin 
(20). We did not find that CRP, or rather the in-
tra-individual changes in CRP and ferritin, was 
associated with changes in responsiveness to ep-
oetin (likely due to only modest within-subject 
changes in these parameters). It is, therefore, un-
certain whether the part of the within-subject 
variability in responsiveness to epoetin that was 
explained by changes in serum albumin was due 
to changes in the inflammatory or nutritional 
status, or both.
In contrast to published evidence, we found 
an association of higher serum iPTH values and 
greater Hb response combined with lower epoe-
tin doses. Several studies suggested that a reduc-
tion of serum iPTH values is associated with an 
improvement in anemia (increase in Hb) or re-
duced epoetin requirements (21). There are 
several potential mechanisms by which severe 
hyperparathyroidism can worsen anemia in pa-
tients with ESRD – a direct toxic effect of PTH 
on erythroid progenitors and induction of mar-
row fibrosis (8). However, the role of hyperpara-
thyroidism in renal anemia and hyporesponsive-
ness to epoetin is relatively minor as compared 
with the relevance of other factors, primarily 
iron deficiency and inflammation (8). Also, there 
seems to be no consensus on the “critical” or 
“cut-off” level of circulating iPTH that would be 
predictive of reduced response to epoetin (21), 
or direct correlation between iPTH levels and 
responsiveness to epoetin as illustrated by epo-
etin dose-demands (22). Furthermore, our anal-
ysis was largely influenced by the fact that there 
were 3 patients who had much higher iPTH val-
ues at the beginning of the epoetin treatment pe-
riod characterized by better responsiveness than 
at the beginning of the epoetin-treatment period 
characterized by poorer responsiveness to epo-
etin. When these 3 patients were excluded from 
the analysis, the findings were the same as report-
ed for the “full data set”, except for the fact that 
there was no statistically significant association 
between the serum iPTH values and the mea-
sures of responsiveness to epoetin. Therefore, 
present observations of the relationship between 
responsiveness to epoetin and serum iPTH val-
ues should be taken with caution.
In conclusion, we performed a post hoc anal-
ysis of data on a cohort of patients with ESRD 
who participated in two consecutive clinical trials 
with epoetin that were separated by a prolonged 
epoetin-free period. Responsiveness to epoetin 
was reduced in the second trial as compared with 
the first one. This within-subject reduction in re-
sponsiveness to epoetin could not be explained 
by the within-subject changes in “classical” con-
founders of response to epoetin. The data suggest 
that the fact that the patients were deprived of 
epoetin (and anemic) between the trials indepen-
dently contributed to reduction of responsive-
ness to epoetin at re-exposure. This implies that 
the practice of epoetin withdrawal commonly 
seen in financially less privileged countries due to 
shortages is not only directly medically harmful 
for the concerned patients, with respect to car-
diovascular morbidity and mortality and quality 
of life, but is also counterproductive in the sense 
that re-installment of treatment requires utiliza-
tion of larger amounts of epoetin for a certain ef-
fect and is, therefore, less cost-effective.
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